JPWO2020180501A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020180501A5
JPWO2020180501A5 JP2021543384A JP2021543384A JPWO2020180501A5 JP WO2020180501 A5 JPWO2020180501 A5 JP WO2020180501A5 JP 2021543384 A JP2021543384 A JP 2021543384A JP 2021543384 A JP2021543384 A JP 2021543384A JP WO2020180501 A5 JPWO2020180501 A5 JP WO2020180501A5
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
acid sequence
mhc class
presenting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021543384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522404A (ja
JP2022522404A5 (https=
JP7691927B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/019244 external-priority patent/WO2020180501A1/en
Publication of JP2022522404A publication Critical patent/JP2022522404A/ja
Publication of JPWO2020180501A5 publication Critical patent/JPWO2020180501A5/ja
Publication of JP2022522404A5 publication Critical patent/JP2022522404A5/ja
Application granted granted Critical
Publication of JP7691927B2 publication Critical patent/JP7691927B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021543384A 2019-03-06 2020-02-21 Ｔ細胞調節抗原提示ポリペプチド及びその使用方法 Active JP7691927B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962814715P 2019-03-06 2019-03-06
US62/814,715 2019-03-06
PCT/US2020/019244 WO2020180501A1 (en) 2019-03-06 2020-02-21 T-cell modulatory antigen-presenting polypeptides and methods of use thereof

Publications (4)

Publication Number Publication Date
JP2022522404A JP2022522404A (ja) 2022-04-19
JPWO2020180501A5 true JPWO2020180501A5 (https=) 2023-03-01
JP2022522404A5 JP2022522404A5 (https=) 2023-03-01
JP7691927B2 JP7691927B2 (ja) 2025-06-12

Family

ID=72338064

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021543384A Active JP7691927B2 (ja) 2019-03-06 2020-02-21 Ｔ細胞調節抗原提示ポリペプチド及びその使用方法

Country Status (4)

Country Link
US (1) US20220106378A1 (https=)
EP (1) EP3935079A4 (https=)
JP (1) JP7691927B2 (https=)
WO (1) WO2020180501A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116970059A (zh) 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
CA3061614A1 (en) 2017-04-28 2018-11-01 The Regents Of The University Of Colorado, A Body Corporate Methods of treating rheumatoid arthritis using rna-guided genome editing of hla gene
TW201920249A (zh) 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
TW202208395A (zh) 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
JP2024517658A (ja) * 2021-04-21 2024-04-23 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節ポリペプチド及びその使用方法
CN117561280A (zh) * 2021-04-21 2024-02-13 库尔生物制药有限公司 携带TGF-β的抗原呈递多肽复合物及其使用方法
CN117396229A (zh) * 2021-04-21 2024-01-12 Cue生物制药股份有限公司 Mhc ii类t细胞调节多肽及其使用方法
JP2024517475A (ja) * 2021-05-10 2024-04-22 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト 自己免疫を治療するための操作されたｈｌａ対立遺伝子
US20240270815A1 (en) * 2021-05-26 2024-08-15 Cue Biopharma, Inc. Antigen Presenting Polypeptide Complexes and Methods of Use Thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
EP1637608B1 (en) 1993-10-25 2009-07-22 CANJI, Inc. Recombinant adenoviral vector and methods of use
JPH10503379A (ja) * 1994-07-29 1998-03-31 デイド・インターナショナル・インコーポレーテッド Ｍｈｃ複合体およびその用途
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
US6811785B2 (en) 2001-05-07 2004-11-02 Mount Sinai School Of Medicine Of New York University Multivalent MHC class II—peptide chimeras
WO2003062370A2 (en) 2001-07-19 2003-07-31 Perlan Therapeutics, Inc. Multimeric proteins and methods of making and using same
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1996937A4 (en) 2006-03-06 2009-04-08 Amunix Inc GENETIC PACKS AND USES THEREOF
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
WO2012007951A1 (en) * 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
US10816554B2 (en) * 2014-04-04 2020-10-27 The Board Of Trustees Of The Leland Stanford Junior University Ligand discovery for T cell receptors
WO2015164714A1 (en) 2014-04-24 2015-10-29 Immusant, Inc. Use of interleukin-2 for diagnosis of celiac disease
PL3157552T3 (pl) 2014-06-18 2020-05-18 Albert Einstein College Of Medicine Polipeptydy syntac i ich zastosowania
RS59340B1 (sr) * 2014-11-06 2019-10-31 Hoffmann La Roche Varijante fc regiona sa modifikovanim vezivanjem za fcrn i metode upotrebe
ES3055030T3 (en) 2015-05-06 2026-02-09 Uti Lp Nanoparticle compositions for sustained therapy
AU2017225787B2 (en) * 2016-03-03 2021-09-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR20190044029A (ko) * 2016-05-18 2019-04-29 알버트 아인슈타인 컬리지 오브 메디슨, 인크. 변이체 pd-l1 폴리펩타이드, t-세포 조절 다량체 폴리펩타이드 및 이들의 사용 방법
MX2019005497A (es) * 2016-11-09 2019-11-18 Uti Lp Moleculas de pmhc de clase ii recombinantes.
EP3678677A4 (en) * 2017-09-07 2021-06-16 Cue Biopharma, Inc. Antigen-presenting polypeptides and methods of use thereof
EP4211149A4 (en) * 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF

Similar Documents

Publication Publication Date Title
JP2021500855A5 (https=)
Born et al. Recognition of a peptide antigen by heat shock--reactive γδ T lymphocytes
AU2018259029B2 (en) TCR and peptides
Todd et al. A molecular basis for genetic susceptibility to insulin-dependent diabetes mellitus
IL95125A (en) T cell peptides receive a method for their selection and preparation, and pharmaceutical preparations containing them
JPWO2020180501A5 (https=)
CN114302962B (zh) 特异性针对来源于ebv抗原的tcr构建体
Tabata et al. Characterization of self-glutamic acid decarboxylase 65-reactive CD4+ T-cell clones established from Japanese patients with insulin-dependent diabetes mellitus
NO308611B1 (no) AnalogifremgangsmÕte for fremstilling av et terapeutisk aktivt peptid
EP3898665B1 (en) Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
NO317049B1 (no) Undertrykkelse av T-celleproliferasjon ved anvendelse av fragmenter av myelinbasisk protein
JP2023527613A (ja) Ｇ１２ｖ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体
JPWO2020181062A5 (https=)
Antonsson et al. Functional characterization of the interaction between the superantigen staphylococcal enterotoxin A and the TCR
EP0286447B1 (en) Method and agents relating to prophylactic treatment of autoimmune diseases
EP0726777A1 (en) Prokaryotic expression of mhc proteins
Abromson-Leeman et al. T cell responses to myelin basic protein in experimental autoimmune encephalomyelitis-resistant BALB/c mice
JP2003524369A (ja) エピトープを有する主要組織適合複合体クラスｉｉエレメント／免疫グロブリンキメラ分子
CN100364611C (zh) 肽基免疫治疗剂
Adams et al. Human T-cell clones to the 70-kilodalton heat shock protein of Mycobacterium leprae define mycobacterium-specific epitopes rather than shared epitopes
CN117651711A (zh) 使用免疫原性肽的改进的治疗方法
AU2756792A (en) Method of producing antibodies to a restricted population of t lymphocytes, antibodies and method of use
Kuhröber et al. Vaccination with T cell receptor peptides primes anti‐receptor cytotoxic T lymphocytes (CTL) and anergizes T cells specifically recognized by these CTL
JPWO2022056014A5 (https=)
KR20230066023A (ko) p53의 R273C 또는 Y220C 돌연변이를 인식하는 T 세포 수용체